Lindt: GLP-1 Users Eating More Chocolate, Not Less

In a surprising twist for the weight-loss and confectionery worlds, Swiss chocolatier Lindt & Spruengli has reported that GLP-1 users in the U.S. are not cutting back on chocolate—in fact, they're driving sales growth faster than the general population. This finding, based on an internal study using February data from market researcher Circana, challenges preconceived notions about how GLP-1 medications like Ozempic and Mounjaro impact everyday indulgences such as chocolate consumption.

The Lindt Internal Study: Key Data on GLP-1 Users and Chocolate Sales

Lindt's analysis paints a clear picture: 15% of U.S. households are using GLP-1s, and these households represent a disproportionate 17.5% of total chocolate sales. Even more notably, U.S. sales of premium chocolate among GLP-1 users increased by nearly 17% in 2025, compared to just a 6.5% rise among non-GLP-1 users.

This data comes directly from Circana, a trusted market research firm, and was highlighted by Lindt on March 10. As the maker of iconic chocolate Easter bunnies, Lindt's insights carry weight in understanding consumer behavior shifts tied to the booming GLP-1 market.

Breaking Down the Numbers

• Household Penetration: 15% of U.S. households on GLP-1s.
• Sales Share: GLP-1 households account for 17.5% of chocolate sales.
• Premium Growth: 17% increase for GLP-1 users vs. 6.5% for others in 2025.

These figures underscore that GLP-1 users, often on drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight management, are maintaining or even boosting their chocolate purchases.

Understanding GLP-1 Medications: How They Work and Why Cravings Persist

GLP-1 receptor agonists, such as Ozempic and Mounjaro, mimic the glucagon-like peptide-1 hormone produced in the gut. This hormone regulates blood sugar, slows gastric emptying, and signals fullness to the brain, leading to reduced appetite and significant weight loss—often 15-20% of body weight in clinical trials.

Despite these effects, the Lindt data suggests chocolate cravings aren't fully suppressed. Possible explanations include:

• Selective Appetite Changes: GLP-1s primarily curb high-calorie, high-fat foods, but sweet treats like chocolate may trigger different reward pathways in the brain.
• Premium Shift: Users might opt for higher-quality, smaller portions of chocolate, aligning with portion control while satisfying hedonic desires.
• Behavioral Adaptation: Long-term users may incorporate treats mindfully into balanced diets.

For patients, this means GLP-1 therapy supports metabolic health but doesn't eliminate enjoyment of favorites like chocolate. Discussing dietary patterns with a healthcare provider can help optimize outcomes.

Challenging Industry Expectations: Analysts vs. Reality

Analysts at Berenberg had anticipated the opposite. They projected that oral GLP-1 weight-loss drugs would negatively impact the food industry, especially confectionery, dragging Lindt's sales volumes by 0.9 percentage points in 2027.

These forecasts assumed broader adoption of GLP-1s would slash demand for indulgent snacks. However, Lindt's real-world data flips the script, showing resilience—and growth—in chocolate sales among users.

The Role of Oral GLP-1 Pills

Upcoming oral GLP-1 formulations are expected to widen access beyond injectable users. These pills may appeal to more men and younger patients, offering milder weight loss compared to injectables like Ozempic. This expansion could further influence consumer habits, but Lindt's findings suggest confectionery demand may hold steady or grow.

Implications for the Food Industry and Chocolate Makers

Lindt's report signals potential stability for premium confectioners. As GLP-1 use surges—with millions of prescriptions monthly—brands focusing on high-quality, portion-friendly products could thrive. This contrasts with fears of a broad "GLP-1 recession" in snacks.

For metabolic health content creators and patients, it highlights the nuanced effects of these drugs on real-life eating. Chocolate, rich in flavonoids from cocoa, may even offer cardiovascular benefits in moderation, complementing GLP-1s' heart-protective properties observed in trials like SELECT.

Practical Guidance for GLP-1 Users: Balancing Chocolate and Weight Goals

If you're on Ozempic, Mounjaro, or similar GLP-1s, Lindt's data reassures that occasional chocolate is compatible with your regimen. Here's how to incorporate it wisely:

• Portion Control: Opt for premium dark chocolate (70%+ cocoa) in 1-oz servings to maximize satisfaction with fewer calories.
• Mindful Timing: Pair with protein or fiber to blunt blood sugar spikes.
• Track Habits: Tools like Shotlee can help log symptoms, side effects, and intake to spot patterns in cravings.
• Consult Professionals: Work with a doctor or dietitian if gastrointestinal side effects (common with GLP-1s, like nausea) affect enjoyment.

Safety note: GLP-1s carry risks like pancreatitis or thyroid concerns; monitor with regular check-ups. Chocolate in excess can hinder goals, so moderation remains key.

Comparisons: GLP-1s vs. Traditional Weight Loss Approaches

Unlike calorie-restrictive diets or older drugs like phentermine, GLP-1s target hormonal pathways for sustainable loss. Yet, as Lindt shows, they don't universally eliminate sweets. Studies on semaglutide note varied craving reductions—savory more than sweet—aligning with this chocolate surge.

Key Takeaways: What Lindt's Findings Mean for Patients and Industry

• GLP-1 users represent 17.5% of U.S. chocolate sales despite 15% household penetration.
• Premium chocolate sales up 17% among users in 2025 vs. 6.5% non-users.
• Defies Berenberg forecasts of confectionery decline.
• Oral GLP-1s may broaden user base without killing chocolate demand.
• Patients: Enjoy treats mindfully; track for best results.

Conclusion: A Sweeter Outlook for GLP-1 Users

Lindt's study, reported by Danny Callaghan and Bernadette Hogg on March 10 via Reuters, reveals that GLP-1 users on Ozempic and Mounjaro are fueling chocolate sales growth. This enriches our understanding of these drugs' real-world impact, emphasizing balanced, enjoyable paths to metabolic health. For personalized advice, consult your physician—sustainable weight management thrives on science, not deprivation.